Johnson & Johnson 2026 Guidance Tops Estimates
Johnson & Johnson 2026 guidance tops estimates and forces traders to reassess positioning as the company absorbs Jan. 8 pricing deal costs.
KEY TAKEAWAYS
- 2026 operational sales guidance of $99.5 billion to $100.5 billion, above the $98.9 billion consensus.
- Adjusted EPS guidance of $11.43 to $11.63, modestly above the $11.45 consensus.
- Guidance incorporates costs from the Jan. 8 voluntary pricing deal estimated at hundreds of millions of dollars.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Johnson & Johnson said on Jan. 21, 2026, that its 2026 guidance will exceed Wall Street forecasts, following a quarterly revenue beat despite a voluntary drug-pricing agreement signed on Jan. 8.
Guidance Above Wall Street Estimates Despite Pricing Deal
The company expects 2026 operational sales between $99.5 billion and $100.5 billion, surpassing the consensus of $98.9 billion. Management described this as more than 5.0% full-year growth. Adjusted earnings per share (EPS) guidance ranges from $11.43 to $11.63, above the $11.45 consensus, reflecting a growth trajectory aligned with sales.
This guidance incorporates costs from a voluntary drug-pricing agreement signed on Jan. 8 via TrumpRx.gov. The deal grants a three-year tariff exemption on pharmaceutical imports in exchange for U.S. prices aligned with international benchmarks. Johnson & Johnson was among 15 signers, excluding AbbVie and Regeneron. CFO Joseph Wolk said the agreement will cost the company "hundreds of millions of dollars" in 2026.
Management said the outlook assumes continued strength in the product mix while offsetting declines in older franchises.
Fourth-Quarter Results Driven by Oncology and MedTech
Johnson & Johnson reported fourth-quarter 2025 sales of $24.6 billion, up 9.1% reported and 7.1% operationally, and full-year sales of $94.2 billion, up 6.0%. The quarterly revenue beat supported the stronger 2026 outlook.
The Innovative Medicines segment generated about $15.8 billion in fourth-quarter sales, rising roughly 10.0% operationally. Oncology sales grew approximately 20.0%, led by Darzalex and Carvykti. Management attributed much of the near-term growth to these oncology franchises.
MedTech contributed $8.8 billion in fourth-quarter revenue, up 5.8% operationally. Cardiovascular sales strengthened following the Shockwave and Abiomed acquisitions, which management highlighted as key contributors to the segment’s performance and the 2026 sales base.
Stelara lost U.S. exclusivity on Jan. 1, 2025, opening the biologic to biosimilar competition such as Amgen’s Wezlana. The company said Tremfya and Darzalex partially offset this erosion. Johnson & Johnson emphasized balancing growth in newer franchises with managing declines in legacy products as central to sustaining growth while absorbing policy costs.
Together, the guidance and quarterly results indicate management’s confidence that oncology and MedTech momentum will more than offset the near-term fiscal impact of the pricing pact and legacy-product pressures, positioning the company for stronger performance in 2026.
